Trastuzumab Recruiting Phase 2 Trials for Estrogen Receptor Negative / HER2/Neu Positive / Stage IV Breast Cancer / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Triple-Negative Breast Carcinoma / Breast Carcinoma Metastatic in the Brain / HER2/Neu Negative Treatment

Indications	Status	Purpose	Phase
DBCOND0036417 (Estrogen Receptor Negative) DBCOND0037939 (HER2/Neu Positive) DBCOND0028550 (Stage IV Breast Cancer) DBCOND0038639 (Progesterone Receptor Negative) DBCOND0030216 (Recurrent Breast Carcinoma) DBCOND0038640 (Triple-Negative Breast Carcinoma) DBCOND0082404 (Breast Carcinoma Metastatic in the Brain) DBCOND0034239 (HER2/Neu Negative)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02774681	Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis	Palbociclib (DB09073) Trastuzumab (DB00072)